AbbVie Inc. (ABBV) on Tuesday reported positive topline results from the Phase 3b/4 head-to-head SELECT-SWITCH study, showing that Rinvoq outperformed Humira in treating adults with moderate to severe rheumatoid arthritis.
The study met its primary endpoint, with Rinvoq demonstrating superiority over Humira in achieving low disease activity. About 43.3% of patients receiving Rinvoq achieved low disease activity compared with 22.4% of those on Humira, while both treatments showed no new safety concerns during the 12-week period.
AbbVie shares were up more than 1% in pre-market trading after closing at $197.38 on Monday.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.